TISIDB

Summary
Symbol	KHDRBS1
Name	KH domain containing, RNA binding, signal transduction associated 1
Aliases	Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Membrane Note=Predominantly located in the nucleus but also located partially in the cytoplasm.
Domain	PF00013 KH domain PF16274 Qua1 domain PF16568 Tyrosine-rich domain of Sam68
Function	Recruited and tyrosine phosphorylated by several receptor systems, for example the T-cell, leptin and insulin receptors. Once phosphorylated, functions as an adapter protein in signal transduction cascades by binding to SH2 and SH3 domain-containing proteins. Role in G2-M progression in the cell cycle. Represses CBP-dependent transcriptional activation apparently by competing with other nuclear factors for binding to CBP. Also acts as a putative regulator of mRNA stability and/or translation rates and mediates mRNA nuclear export. Positively regulates the association of constitutive transport element (CTE)-containing mRNA with large polyribosomes and translation initiation. According to some authors, is not involved in the nucleocytoplasmic export of unspliced (CTE)-containing RNA species according to (PubMed:22253824). RNA-binding protein that plays a role in the regulation of alternative splicing and influences mRNA splice site selection and exon inclusion. Binds to RNA containing 5'-[AU]UAA-3' as a bipartite motif spaced by more than 15 nucleotides. Binds poly(A). Can regulate CD44 alternative splicing in a Ras pathway-dependent manner (By similarity). In cooperation with HNRNPA1 modulates alternative splicing of BCL2L1 by promoting splicing toward isoform Bcl-X(S), and of SMN1 (PubMed:17371836, PubMed:20186123). Can regulate alternative splicing of NRXN1 and NRXN3 in the laminin G-like domain 6 containing the evolutionary conserved neurexin alternative spliced segment 4 (AS4) involved in neurexin selective targeting to postsynaptic partners. In a neuronal activity-dependent manner cooperates synergistically with KHDRBS2/SLIM-1 in regulation of NRXN1 exon skipping at AS4. The cooperation with KHDRBS2/SLIM-1 is antagonistic for regulation of NXRN3 alternative splicing at AS4 (By similarity). ; FUNCTION: Isoform 3, which is expressed in growth-arrested cells only, inhibits S phase.

> Gene Ontology [ TOP ]
Biological Process	GO:0000086 G2/M transition of mitotic cell cycle GO:0006397 mRNA processing GO:0006403 RNA localization GO:0006405 RNA export from nucleus GO:0006413 translational initiation GO:0006417 regulation of translation GO:0006446 regulation of translational initiation GO:0006913 nucleocytoplasmic transport GO:0007050 cell cycle arrest GO:0010608 posttranscriptional regulation of gene expression GO:0015931 nucleobase-containing compound transport GO:0032239 regulation of nucleobase-containing compound transport GO:0032241 positive regulation of nucleobase-containing compound transport GO:0032386 regulation of intracellular transport GO:0032388 positive regulation of intracellular transport GO:0034248 regulation of cellular amide metabolic process GO:0034250 positive regulation of cellular amide metabolic process GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044839 cell cycle G2/M phase transition GO:0045727 positive regulation of translation GO:0045786 negative regulation of cell cycle GO:0045948 positive regulation of translational initiation GO:0046822 regulation of nucleocytoplasmic transport GO:0046824 positive regulation of nucleocytoplasmic transport GO:0046831 regulation of RNA export from nucleus GO:0046833 positive regulation of RNA export from nucleus GO:0050657 nucleic acid transport GO:0050658 RNA transport GO:0051168 nuclear export GO:0051169 nuclear transport GO:0051236 establishment of RNA localization
Molecular Function	GO:0003727 single-stranded RNA binding GO:0005070 SH3/SH2 adaptor activity GO:0008143 poly(A) binding GO:0008187 poly-pyrimidine tract binding GO:0008266 poly(U) RNA binding GO:0017124 SH3 domain binding GO:0030674 protein binding, bridging GO:0035591 signaling adaptor activity GO:0060090 binding, bridging GO:0070717 poly-purine tract binding
Cellular Component	GO:0070618 Grb2-Sos complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-8849468: PTK6 Regulates Proteins Involved in RNA Processing R-HSA-162582: Signal Transduction R-HSA-8848021: Signaling by PTK6

Summary
Symbol	KHDRBS1
Name	KH domain containing, RNA binding, signal transduction associated 1
Aliases	Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KHDRBS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	KHDRBS1
Name	KH domain containing, RNA binding, signal transduction associated 1
Aliases	Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KHDRBS1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.85	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KHDRBS1
Name	KH domain containing, RNA binding, signal transduction associated 1
Aliases	Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KHDRBS1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.152	0.362
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.213	0.939
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.111	0.957
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.391	0.32
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.305	0.891
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.505	0.865
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.023	0.958
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.047	0.982
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.012	0.996
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.348	0.85
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.687	0.806
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.121	0.00443

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KHDRBS1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KHDRBS1
Name	KH domain containing, RNA binding, signal transduction associated 1
Aliases	Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KHDRBS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KHDRBS1
Name	KH domain containing, RNA binding, signal transduction associated 1
Aliases	Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KHDRBS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KHDRBS1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KHDRBS1
Name	KH domain containing, RNA binding, signal transduction associated 1
Aliases	Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KHDRBS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KHDRBS1
Name	KH domain containing, RNA binding, signal transduction associated 1
Aliases	Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KHDRBS1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KHDRBS1
Name	KH domain containing, RNA binding, signal transduction associated 1
Aliases	Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KHDRBS1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KHDRBS1
Name	KH domain containing, RNA binding, signal transduction associated 1
Aliases	Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location	1p32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KHDRBS1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse KHDRBS1